How Analysts Feel About MEI Pharma Inc (MEIP) After Today’s Huge Increase?

September 17, 2017 - By Adrian Erickson

The stock of MEI Pharma Inc (NASDAQ:MEIP) is a huge mover today! The stock increased 4.17% or $0.11 on September 15, reaching $2.75. About 241,693 shares traded or 4.96% up from the average. MEI Pharma Inc (NASDAQ:MEIP) has risen 20.90% since September 17, 2016 and is uptrending. It has outperformed by 4.20% the S&P500.
The move comes after 8 months positive chart setup for the $97.52M company. It was reported on Sep, 17 by Barchart.com. We have $3.00 PT which if reached, will make NASDAQ:MEIP worth $8.78 million more.

Investors wait MEI Pharma Inc (NASDAQ:MEIP) to report on November, 14. its quarterly earnings Wall Street analysts expect $-0.17 EPS, down $0.05 or 41.67 % from last year’s $-0.12 same quarter earnings. MEI Pharma Inc’s Wall Street analysts see 41.67 % negative EPS growth, taking into account the $-0.12 EPS reproted in the previous quarter,

MEI Pharma Inc (NASDAQ:MEIP) Ratings Coverage

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. Stifel Nicolaus maintained MEI Pharma Inc (NASDAQ:MEIP) rating on Wednesday, September 6. Stifel Nicolaus has “Hold” rating and $2.5 target. The stock has “Buy” rating by Oppenheimer on Wednesday, May 31. Oppenheimer maintained MEI Pharma Inc (NASDAQ:MEIP) on Wednesday, June 14 with “Buy” rating. The firm earned “Buy” rating on Wednesday, August 2 by Oppenheimer. Wedbush maintained MEI Pharma Inc (NASDAQ:MEIP) on Friday, September 4 with “Hold” rating. On Monday, June 26 the stock rating was maintained by Oppenheimer with “Buy”.

More notable recent MEI Pharma Inc (NASDAQ:MEIP) news were published by: Prnewswire.com which released: “MEI Pharma Reports Second Quarter Fiscal Year 2017 Results” on February 08, 2017, also Seekingalpha.com with their article: “MEI Pharma: Double Trouble Or Double Double?” published on July 11, 2017, Prnewswire.com published: “Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation …” on May 18, 2017. More interesting news about MEI Pharma Inc (NASDAQ:MEIP) were released by: 247Wallst.com and their article: “Can MEI Pharma Rise Nearly 300%?” published on May 25, 2017 as well as Nasdaq.com‘s news article titled: “MEI Pharma-Presage Biosciences on License Deal for Voruciclib” with publication date: September 06, 2017.

MEI Pharma, Inc. is an oncology company. The company has market cap of $97.52 million. The Firm is focused on the clinical development of drugs and therapies for treatment of cancer. It has a 41.12 P/E ratio. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.